Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $97.2 million.

  • aTYR PHARMA's Shares Outstanding (Diluted Average) rose 2816.81% to $97.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.2 million, marking a year-over-year increase of 2816.81%. This contributed to the annual value of $74.3 million for FY2024, which is 3853.04% up from last year.
  • aTYR PHARMA's Shares Outstanding (Diluted Average) amounted to $97.2 million in Q3 2025, which was up 2816.81% from $90.1 million recorded in Q2 2025.
  • aTYR PHARMA's Shares Outstanding (Diluted Average)'s 5-year high stood at $97.2 million during Q3 2025, with a 5-year trough of $14.1 million in Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $50.1 million, with a median of $53.6 million in 2023.
  • Per our database at Business Quant, aTYR PHARMA's Shares Outstanding (Diluted Average) surged by 10830.04% in 2021 and then skyrocketed by 2467.46% in 2025.
  • Over the past 5 years, aTYR PHARMA's Shares Outstanding (Diluted Average) (Quarter) stood at $19.1 million in 2021, then surged by 48.94% to $28.4 million in 2022, then soared by 88.63% to $53.6 million in 2023, then soared by 38.53% to $74.3 million in 2024, then soared by 30.83% to $97.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $97.2 million for Q3 2025, versus $90.1 million for Q2 2025 and $86.5 million for Q1 2025.